See more : EcoSynthetix Inc. (ECSNF) Income Statement Analysis – Financial Results
Complete financial analysis of IsoPlexis Corporation (ISO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IsoPlexis Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Motion Acquisition Corp. (MOTNU) Income Statement Analysis – Financial Results
- Sensys Gatso Group AB (publ) (SGG.ST) Income Statement Analysis – Financial Results
- Pidilite Industries Limited (PIDILITIND.NS) Income Statement Analysis – Financial Results
- HINDUSTAN APPLIANCES LTD. (HINDAPL.BO) Income Statement Analysis – Financial Results
- Steep Hill Inc. (STPH.CN) Income Statement Analysis – Financial Results
IsoPlexis Corporation (ISO)
About IsoPlexis Corporation
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 16.76M | 17.26M | 10.39M | 7.51M |
| Cost of Revenue | 17.69M | 8.49M | 4.97M | 3.26M |
| Gross Profit | -925.00K | 8.77M | 5.41M | 4.25M |
| Gross Profit Ratio | -5.52% | 50.79% | 52.11% | 56.59% |
| Research & Development | 23.50M | 20.97M | 11.16M | 10.13M |
| General & Administrative | 42.68M | 26.35M | 8.02M | 4.81M |
| Selling & Marketing | 29.88M | 37.77M | 13.51M | 7.56M |
| SG&A | 72.56M | 64.12M | 21.53M | 12.37M |
| Other Expenses | -494.00K | -1.63M | -4.12M | -4.64M |
| Operating Expenses | 95.57M | 85.09M | 28.57M | 17.86M |
| Cost & Expenses | 113.25M | 93.58M | 33.55M | 21.12M |
| Interest Income | 0.00 | 0.00 | 3.00K | 0.00 |
| Interest Expense | 5.34M | 3.62M | 21.00K | 1.00K |
| Depreciation & Amortization | 9.69M | 679.00K | 882.00K | 498.00K |
| EBITDA | -91.54M | -76.32M | -22.28M | -13.12M |
| EBITDA Ratio | -546.17% | -438.31% | -214.49% | -174.78% |
| Operating Income | -101.23M | -76.32M | -23.16M | -13.62M |
| Operating Income Ratio | -603.96% | -442.25% | -222.98% | -181.41% |
| Total Other Income/Expenses | -4.77M | -5.25M | -103.00K | -11.00K |
| Income Before Tax | -106.00M | -81.57M | -23.26M | -13.63M |
| Income Before Tax Ratio | -632.40% | -472.64% | -223.97% | -181.56% |
| Income Tax Expense | 9.51M | 1.99M | 21.00K | 1.00K |
| Net Income | -115.50M | -83.56M | -23.29M | -13.63M |
| Net Income Ratio | -689.12% | -484.18% | -224.17% | -181.57% |
| EPS | -2.94 | -8.16 | -0.60 | -0.35 |
| EPS Diluted | -2.94 | -8.16 | -0.60 | -0.35 |
| Weighted Avg Shares Out | 39.32M | 10.24M | 38.84M | 38.84M |
| Weighted Avg Shares Out (Dil) | 39.32M | 10.24M | 38.84M | 38.84M |
Ugandans urged to embrace new market opportunities in South Sudan
Bandwidth Achieves Comprehensive ISO 27001 Certification Across Global Network, APIs, People and Business Processes
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022
IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript
IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
IsoPlexis to Participate in Three Upcoming Investor Conferences
U.S. IPO Weekly Recap: Healthcare And Canadian Crosslistings Lead An 8 IPO Week
IsoPlexis, a company uncovering a ‘new layer' of cell data, aims for $125M in market debut
IsoPlexis IPO priced in the middle of expected range, as the biotech raised $125 million
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
Source: https://incomestatements.info
Category: Stock Reports